Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
The University of Texas MD Anderson Cancer Center · Medical College of Wisconsin · +1 more institution
Abstract
PURPOSE: Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM. PATIENTS AND METHODS: This phase III trial enrolled patients older than age 18 years with a Karnofsky performance score of ≥ 60 with adequate tissue. Stratification included clinical factors and tumor…
Citation impact
- FWCI
- 34.36
- Percentile
- 100%
- References
- 25
Authors
20- MRMark R. GilbertCorresponding
The University of Texas MD Anderson Cancer Center
- MWMeihua Wang
The University of Texas MD Anderson Cancer Center
- KAKenneth Aldape
The University of Texas MD Anderson Cancer Center
- RSRoger Stupp
The University of Texas MD Anderson Cancer Center
- MEMonika E. Hegi
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Temozolomide
- Medicine
- Internal medicine
- Clinical endpoint
- Hazard ratio
- Oncology
- Concomitant
- Progression-free survival
- Good health and well-being